



A Public Entity

Inland Empire Health Plan

<h1>PHARMACY TIMES</h1> <p>BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT February 2022</p>

Medi-Cal Rx Transition: Continuous Glucose Monitors (CGM) UPDATE

Dear IPA Partners,

We thank you for your patience as we finalize a DOFR amendment to reflect the recent Medi-Cal Rx changes affecting our Member population. IEHP leadership has determined based on concerns about potential delays in the delivery of CGM monitors and supplies that it is necessary to update how CGMs may be covered by either Magellan or IEHP and its delegates. Please review the updated information below.

Type 1 Continuous Glucose Monitor (GCM) coverage has been updated.

Providers can now either submit an authorization request to the State PBM Magellan **OR** to IEHP or the Member’s respective IPA for Type 1 CGM Monitors and Supplies. Providers should indicate DME Providers as the servicing provider. Please see the updated summary of coverage below:

Member Diagnosis	Device Type	Billing
Type 1 Diabetes	Therapeutic CGM Monitor and Supplies	Submit to Medi-Cal Rx (Magellan) OR IEHP Direct: submit eAuth to IEHP with DME Providers indicated as servicing provider IPA: authorization request should be submitted to IPA
	Non-Therapeutic CGM Monitor	Not a covered benefit
	Non-Therapeutic CGM Supplies	IEHP Direct: submit eAuth to IEHP with DME Providers indicated as servicing provider IPA: authorization request should be submitted to IPA
Type 2 Diabetes	Therapeutic CGM Monitor and Supplies	IEHP Direct: submit eAuth to IEHP with DME Providers indicated as servicing provider IPA: authorization request should be submitted to IPA
	Non-Therapeutic CGM Monitor	Not covered benefit
	Non-Therapeutic CGM Supplies	IEHP Direct: submit eAuth to IEHP with DME Providers indicated as servicing provider IPA: authorization request should be submitted to IPA

What is the difference between a therapeutic and non-therapeutic CGM?

DHCS states CGM devices not having FDA designation as a therapeutic CGM are considered “nontherapeutic” CGMs and are considered as an “adjunct use” to blood glucose monitor testing. Diabetic treatment decisions must still be made using a home blood glucose monitor test.

If you have any questions regarding Provider-related issues, please contact the Provider Relations Team at **(909) 890-2054** or **(866) 223-4347** or email ProviderServices@iehp.org.

If you have any additional questions, please feel free to contact the Pharmacy Team at **(909) 890-2049**, between 8:00 AM-5:00 PM, Monday through Friday.

As a reminder, all communications sent by IEHP can also be found on our Provider portal at: www.iehp.org > For Providers > Plan Updates > Correspondences

Visit the new Medi-Cal Rx web site www.Medi-CalRx.dhcs.ca.gov for general information, including Frequently Asked Questions (FAQs) and the Medi-Cal Rx Pharmacy Transition Policy.

Sincerely,

IEHP Pharmaceutical Services